Saturn V Capital Management LP 13F: Quarter-over-Quarter Portfolio Changes
Saturn V Capital Management LP reported a disclosed portfolio value of approximately $697.5 million in its latest SEC Form 13F-HR filing for Q2 2026, up 26.3% quarter on quarter. Over the quarter, the fund initiated 3 new positions, bought more shares in 13 holdings, trimmed 6 holdings, and exited 1 position.
Saturn V Capital Management LP's top buy was a new stake in Trevi Therapeutics INC (TRVI) , equal to 2.8% of the disclosed portfolio. Its top sell was Cogent Biosciences INC (COGT) . The fund exited the position completely after it had accounted for 4.4% of the previous portfolio.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| TREVI THERAPEUTICS INC | TRVI | 2.8% | Holders → |
| SAGIMET BIOSCIENCES INC | SGMT | 1.6% | Holders → |
| VIR BIOTECHNOLOGY INC | VIR | 1.1% | Holders → |
Top BuysQ2 2026
Showing the top 10 buys among 13 existing positions where the fund bought more shares in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| ZURA BIO LTD | ZURA | +1.0% | +184.0% | Holders → |
| ALTO NEUROSCIENCE INC | ANRO | +0.3% | +105.4% | Holders → |
| OCULIS HOLDING AG | OCS | +-1.1% | +32.5% | Holders → |
| CELCUITY INC | CELC | +-0.3% | +31.4% | History → |
| IMMIX BIOPHARMA INC | IMMX | +0.8% | +26.1% | History → |
| DISC MEDICINE INC | IRON | +0.3% | +16.6% | History → |
| CANDEL THERAPEUTICS INC | CADL | +2.3% | +14.1% | History → |
| DYNE THERAPEUTICS INC | DYN | +0.2% | +9.4% | Holders → |
| PHARVARIS N V | PHVS | +0.4% | +9.4% | History → |
| X4 PHARMACEUTICALS INC | XFOR | +-0.2% | +8.0% | Holders → |
Top SellsQ2 2026
The fund's top sells among positions it retained in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| OVID THERAPEUTICS INC | OVID | -1.4% | 84.1% | Holders → |
| INVIVYD INC | IVVD | -1.5% | 23.4% | Holders → |
| MONOPAR THERAPEUTICS INC | MNPR | 0.7% | 9.7% | Holders → |
| ALUMIS INC | ALMS | -1.0% | 9.0% | History → |
| ABIVAX SA | ABVX | -1.0% | 4.4% | History → |
| JAZZ PHARMACEUTICALS PLC | JAZZ | -0.0% | 1.2% | History → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| COGENT BIOSCIENCES INC | COGT | 4.4% |
Net Portfolio Value ChangeQ2 2026
- $0.6BPrior quarter
- $0.7BCurrent quarter
- +$0.1BNet delta
- +26.3%% change
Methodology & FAQ
How Saturn V Capital Management LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Saturn V Capital Management LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Saturn V Capital Management LP buy in Q2 2026?
In Q2 2026, Saturn V Capital Management LP initiated 3 new positions (TREVI THERAPEUTICS INC (TRVI), SAGIMET BIOSCIENCES INC (SGMT), VIR BIOTECHNOLOGY INC (VIR)); bought more shares of ZURA BIO LTD (ZURA), ALTO NEUROSCIENCE INC (ANRO), OCULIS HOLDING AG (OCS), CELCUITY INC (CELC), IMMIX BIOPHARMA INC (IMMX) (the largest 5 of 13 adds).
What stocks did Saturn V Capital Management LP sell in Q2 2026?
In Q2 2026, Saturn V Capital Management LP fully sold 1 position (COGENT BIOSCIENCES INC (COGT)); reduced holdings in OVID THERAPEUTICS INC (OVID), INVIVYD INC (IVVD), MONOPAR THERAPEUTICS INC (MNPR), ALUMIS INC (ALMS), ABIVAX SA (ABVX) (the largest 5 of 6 reductions).
Which positions did Saturn V Capital Management LP initiate in Q2 2026?
Saturn V Capital Management LP established 3 new positions in Q2 2026: TREVI THERAPEUTICS INC (TRVI, 2.8%), SAGIMET BIOSCIENCES INC (SGMT, 1.6%), VIR BIOTECHNOLOGY INC (VIR, 1.1%).
Which existing positions saw the largest allocation increases for Saturn V Capital Management LP in Q2 2026?
Of 13 existing positions with share-count increases in Q2 2026, the largest were: ZURA BIO LTD (ZURA, +1.0% weight, +184.0% shares), ALTO NEUROSCIENCE INC (ANRO, +0.3% weight, +105.4% shares), OCULIS HOLDING AG (OCS, +-1.1% weight, +32.5% shares), CELCUITY INC (CELC, +-0.3% weight, +31.4% shares), IMMIX BIOPHARMA INC (IMMX, +0.8% weight, +26.1% shares), DISC MEDICINE INC (IRON, +0.3% weight, +16.6% shares), CANDEL THERAPEUTICS INC (CADL, +2.3% weight, +14.1% shares), DYNE THERAPEUTICS INC (DYN, +0.2% weight, +9.4% shares), PHARVARIS N V (PHVS, +0.4% weight, +9.4% shares), X4 PHARMACEUTICALS INC (XFOR, +-0.2% weight, +8.0% shares).
Which positions did Saturn V Capital Management LP fully exit in Q2 2026?
Saturn V Capital Management LP fully exited 1 position in Q2 2026: COGENT BIOSCIENCES INC (COGT, last-reported weight 4.4%).
Which existing positions saw the largest allocation reductions for Saturn V Capital Management LP in Q2 2026?
Of 6 existing positions with share-count reductions in Q2 2026, the largest were: OVID THERAPEUTICS INC (OVID, -1.4% weight, -84.1% shares), INVIVYD INC (IVVD, -1.5% weight, -23.4% shares), MONOPAR THERAPEUTICS INC (MNPR, 0.7% weight, -9.7% shares), ALUMIS INC (ALMS, -1.0% weight, -9.0% shares), ABIVAX SA (ABVX, -1.0% weight, -4.4% shares), JAZZ PHARMACEUTICALS PLC (JAZZ, -0.0% weight, -1.2% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.